Identification of a receptor required for the anti-inflammatory activity of IVIG.
about
B cells with regulatory properties in transplantation toleranceInduction of Regulatory T Cells by Intravenous Immunoglobulin: A Bridge between Adaptive and Innate ImmunityGlycans in the immune system and The Altered Glycan Theory of Autoimmunity: a critical reviewFc glycans of therapeutic antibodies as critical quality attributesFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeuticsA perspective on the structure and receptor binding properties of immunoglobulin G FcTranslating basic mechanisms of IgG effector activity into next generation cancer therapiesIntravenous immunoglobulin and Alzheimer's disease: what now?Understanding the role of antibodies in murine infections with Heligmosomoides (polygyrus) bakeri: 35 years ago, now and 35 years aheadInfection, inflammation and host carbohydrates: a Glyco-Evasion HypothesisUnique carbohydrate-carbohydrate interactions are required for high affinity binding between Fc RIII and antibodies lacking core fucoseCrystal structure of sialylated IgG Fc: Implications for the mechanism of intravenous immunoglobulin therapyStructural Characterization of Anti-Inflammatory Immunoglobulin G Fc ProteinsAntigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodiesIgG antibodies to cyclic citrullinated peptides exhibit profiles specific in terms of IgG subclasses, Fc-glycans and a fab-Peptide sequenceAnalysis and functional consequences of increased Fab-sialylation of intravenous immunoglobulin (IVIG) after lectin fractionationComparative Evaluation of the Chemical Stability of 4 Well-Defined Immunoglobulin G1-Fc GlycoformsSphingosine 1-Phosphate Receptor 3-Deficient Dendritic Cells Modulate Splenic Responses to Ischemia-Reperfusion Injury.Mechanisms of tolerance induction in allergic disease: integrating current and emerging concepts.Intravenous immunoglobulins modulate neutrophil activation and vascular injury through FcγRIII and SHP-1.FcγRIIB and autoimmunity.Mechanisms of action of intravenous immunoglobulins.Enrichment of sialylated IgG by lectin fractionation does not enhance the efficacy of immunoglobulin G in a murine model of immune thrombocytopenia.Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin.IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1.Fully recombinant IgG2a Fc multimers (stradomers) effectively treat collagen-induced arthritis and prevent idiopathic thrombocytopenic purpura in miceB cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.High-dose methylprednisolone pulse therapy upregulated FcγRIIb expression on B cells in primary Sjögren's syndrome patients with thrombocytopenia.Sweetened antibodies against humoral autoimmunity: sialylated antibodies are required for IVIg-mediated therapy.Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity.Pathogenesis and Therapeutic Mechanisms in Immune Thrombocytopenia (ITP)The N-Glycosylation of Mouse Immunoglobulin G (IgG)-Fragment Crystallizable Differs Between IgG Subclasses and Strains.Passively administered pooled human immunoglobulins exert IL-10 dependent anti-inflammatory effects that protect against fatal HSV encephalitis.Puzzling inefficiency of H5N1 influenza vaccines in Egyptian poultryAnti-inflammatory IgG production requires functional P1 promoter in β-galactoside α2,6-sialyltransferase 1 (ST6Gal-1) geneAdult invasive and noninvasive infections due to Streptococcus dysgalactiae subsp. equisimilis in France from 2006 to 2010IgG subclasses and allotypes: from structure to effector functions.Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's diseaseImmunoglobulin G (IgG) Fab glycosylation analysis using a new mass spectrometric high-throughput profiling method reveals pregnancy-associated changes
P2860
Q26771404-94F9819D-0FAD-4C83-B4BC-944C9D3B4E62Q26781290-22A1921A-4025-447F-A4CE-4328BAC57C87Q26782025-525DAAEB-5EEE-487B-92C3-478B228BCD47Q26799266-91CAE5FF-017B-4229-BD59-29DAFD4376BFQ26822421-05A970E1-3508-4DEB-954E-6C4046E11184Q26827579-1728828E-9E71-45BA-A547-0F30D1FE4792Q26991899-6D429CD1-703E-4C9A-B097-035A2718A9FFQ27000371-E957162F-6F28-4C19-9236-FC8326C9538BQ27004109-5EA5BB8F-4530-4F17-ACDB-442ABD9A30C5Q27010099-30FC5589-F404-4F9F-A6B0-1AD347E65376Q27670877-805B4645-7D73-42C0-AE73-F07E37D1352FQ27679470-7F555969-CC43-438C-B0FF-616C1AAF48EAQ27684721-BF78E7C2-AD5F-4BA7-928D-A05768DA31C8Q27687250-ACD62BA1-EFA1-4775-8137-0FAB20C39D01Q28069362-53891E77-2383-4886-842E-B736B50C5AAFQ28545233-BE0491AA-D6D8-47A2-BDC1-4034653AECA9Q28728886-2432621F-A5CC-4ED3-908C-2ED1BC21263BQ28820826-583E8492-ED24-47DF-839C-C5DE299C113BQ30278837-A67B43E9-BF1C-46B0-A16A-93EB4039F678Q30371304-4B25AA14-05E2-42F6-BC2D-F8976343D42EQ30514056-42FF458B-A461-4C57-B8B6-40DF249E217EQ30981881-690866D4-5EEE-4AAB-BE1A-1E775CC805EFQ33389428-8E609642-AF10-49A2-86E0-3381600AD50FQ33396115-17A12E2A-B2B2-4D6A-87C6-9694A547006CQ33399238-081A2B43-3A46-43A0-A256-2E9BF14D0477Q33399346-4FB95303-57F8-4CFF-AFF9-855D41C6EF96Q33402880-F305DC53-B5DB-49E0-9240-3308D656F156Q33403107-7577DDAC-E4C1-4FE7-89D9-20DF344AC452Q33409534-54899836-BF42-415A-A507-B3AB85401161Q33414406-25ACD364-A600-4BD6-ABA4-4FFF1A862F2BQ33420853-3BAA807D-43DB-4602-99C3-7BC6CAF436CCQ33439412-6F5D9049-DECC-4645-86A7-192C44B4DD32Q33740762-63FCA3C0-6D13-46B4-8431-8A7B0EA0A25EQ33926907-35C86235-C1ED-4483-8148-3D4134870E8CQ33934663-CDCAFDF1-A357-447E-AE45-D4E2D5C9F8BBQ34199547-293BFD53-E8AB-49E9-8DF5-CDBC98D720F9Q34346177-03F792BE-73FA-451C-B0D7-D0D8470895D8Q34368678-48F689BE-80CA-413F-A1A4-1B65DF7089D5Q34419295-9F02AF3B-0986-4B24-B941-5E1D2DA5173EQ34468348-1BB0AD47-1257-41D2-938B-5D75B3DCB7B1
P2860
Identification of a receptor required for the anti-inflammatory activity of IVIG.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Identification of a receptor required for the anti-inflammatory activity of IVIG.
@en
Identification of a receptor required for the anti-inflammatory activity of IVIG.
@nl
type
label
Identification of a receptor required for the anti-inflammatory activity of IVIG.
@en
Identification of a receptor required for the anti-inflammatory activity of IVIG.
@nl
prefLabel
Identification of a receptor required for the anti-inflammatory activity of IVIG.
@en
Identification of a receptor required for the anti-inflammatory activity of IVIG.
@nl
P2093
P2860
P356
P1476
Identification of a receptor required for the anti-inflammatory activity of IVIG
@en
P2093
Jeffrey V Ravetch
Mikael C I Karlsson
Robert M Anthony
P2860
P304
19571-19578
P356
10.1073/PNAS.0810163105
P407
P577
2008-11-26T00:00:00Z